公开(公告)号：US07799899B2

公开(公告)日：2010-09-21

申请号：US10553491

申请日：2004-04-16

申请人： Heidi Ackerly ,  Avi Ashkenazi ,  David Eberhard ,  Gretchen Frantz ,  Dorothy French ,  Germaine G. Fuh ,  Jo-Anne S. Hongo ,  Chingwei V. Lee ,  Scot A. Masters ,  Helga A. Raab ,  Evgeny Varfolomeev ,  Beni B. Wolf ,  Robert Maurice Pitti ,  Liliana Soroceanu

发明人： Heidi Ackerly ,  Avi Ashkenazi ,  David Eberhard ,  Gretchen Frantz ,  Dorothy French ,  Germaine G. Fuh ,  Jo-Anne S. Hongo ,  Chingwei V. Lee ,  Scot A. Masters ,  Helga A. Raab ,  Evgeny Varfolomeev ,  Beni B. Wolf ,  Robert Maurice Pitti ,  Liliana Soroceanu

IPC分类号： C07K16/00

CPC分类号： C07K16/32 ,  C07K16/22 ,  C07K16/4283 ,  C07K2317/24 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622

摘要： The present invention provides novel polypeptides, antibodies, antagonists, agonists, potentiators, nucleic acid molecules, compositions and methods relating to the STOP-1 polypeptide that are useful for treating and preventing diseases and for medical diagnosis and research. The present invention also provides consensus sequences and specific sequences for antibodies that specifically bind to STOP-1 that are useful in the methods described herein.

摘要翻译： 本发明提供了可用于治疗和预防疾病和医学诊断和研究的新型多肽，抗体，拮抗剂，激动剂，增效剂，核酸分子，与STOP-1多肽相关的组合物和方法。 本发明还提供了与本文所述方法有用的特异性结合STOP-1的抗体的共有序列和特异性序列。

公开(公告)号：US20080050377A1

公开(公告)日：2008-02-28

申请号：US10553491

申请日：2004-04-16

申请人： Heidi Ackerly ,  Avi Ashkenazi ,  David Eberhard ,  Gretchen Frantz ,  Dorothy French ,  Germaine G. Fuh ,  Jo-Anne S. Hongo ,  Chingwei V. Lee ,  Scot A. Marsters ,  Helga A. Raab ,  Evgeny Varfolomeev ,  Beni B. Wolf ,  Robert Maurice Pitti ,  Liliana Soroceanu

发明人： Heidi Ackerly ,  Avi Ashkenazi ,  David Eberhard ,  Gretchen Frantz ,  Dorothy French ,  Germaine G. Fuh ,  Jo-Anne S. Hongo ,  Chingwei V. Lee ,  Scot A. Marsters ,  Helga A. Raab ,  Evgeny Varfolomeev ,  Beni B. Wolf ,  Robert Maurice Pitti ,  Liliana Soroceanu

IPC分类号： C07K16/30 ,  A61K39/395 ,  A61P35/00 ,  C12N1/00 ,  C12N15/63 ,  G01N33/574 ,  G01N33/53 ,  C12N15/13 ,  C07K14/435 ,  C07K16/18

CPC分类号： C07K16/32 ,  C07K16/22 ,  C07K16/4283 ,  C07K2317/24 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622

摘要： The present invention provides novel polypeptides, antibodies, antagonists, agonists, potentiators, nucleic acid molecules, compositions and methods relating to the STOP-1 polypeptide that are useful for treating and preventing diseases and for medical diagnosis and research. The present invention also provides consensus sequences and specific sequences for antibodies that specifically bind to STOP-1 that are useful in the methods described herein.

摘要翻译： 本发明提供了可用于治疗和预防疾病和医学诊断和研究的新型多肽，抗体，拮抗剂，激动剂，增效剂，核酸分子，与STOP-1多肽相关的组合物和方法。 本发明还提供了与本文所述方法有用的特异性结合STOP-1的抗体的共有序列和特异性序列。

公开(公告)号：US20110112279A1

公开(公告)日：2011-05-12

申请号：US12845470

申请日：2010-07-28

申请人： HEIDI ACKERLY ,  Avi Ashkenazi ,  David Eberhard ,  Gretchen Frantz ,  Dorothy French ,  Germaine G. Fuh ,  Jo-Anne S. Hongo ,  Chingwei V. Lee ,  Scot A. Marsters ,  Helga A. Raab ,  Evgeny Varfolomeev ,  Beni B. Wolf ,  Robert Maurice Pitti ,  Liliana Soroceanu

发明人： HEIDI ACKERLY ,  Avi Ashkenazi ,  David Eberhard ,  Gretchen Frantz ,  Dorothy French ,  Germaine G. Fuh ,  Jo-Anne S. Hongo ,  Chingwei V. Lee ,  Scot A. Marsters ,  Helga A. Raab ,  Evgeny Varfolomeev ,  Beni B. Wolf ,  Robert Maurice Pitti ,  Liliana Soroceanu

IPC分类号： C07K16/18

CPC分类号： C07K16/32 ,  C07K16/22 ,  C07K16/4283 ,  C07K2317/24 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622

摘要： The present invention provides novel polypeptides, antibodies, antagonists, agonists, potentiators, nucleic acid molecules, compositions and methods relating to the STOP-1 polypeptide that are useful for treating and preventing diseases and for medical diagnosis and research. The present invention also provides consensus sequences and specific sequences for antibodies that specifically bind to STOP-1 that are useful in the methods described herein.

摘要翻译： 本发明提供了可用于治疗和预防疾病和医学诊断和研究的新型多肽，抗体，拮抗剂，激动剂，增效剂，核酸分子，与STOP-1多肽相关的组合物和方法。 本发明还提供了与本文所述方法有用的特异性结合STOP-1的抗体的共有序列和特异性序列。

公开(公告)号：US20060211060A1

公开(公告)日：2006-09-21

申请号：US11377530

申请日：2006-03-16

申请人： John Haley ,  Graeme Griffin ,  Lukas Amler ,  David Eberhard ,  Robert Yauch

发明人： John Haley ,  Graeme Griffin ,  Lukas Amler ,  David Eberhard ,  Robert Yauch

IPC分类号： G01N33/574

CPC分类号： A61K31/517 ,  G01N33/5011 ,  G01N33/57407 ,  G01N33/57484 ,  G01N2800/52

摘要： The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with an EGFR kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an EGFR kinase inhibitor, comprising assessing whether the tumor cell has undergone an epithelial to mesenchymal transition (EMT), by determining the expression level of epithelial and/or mesenchymal biomarkers, wherein tumor cells that have undergone an EMT are substantially less sensitive to inhibition by EGFR kinase inhibitors. Improved methods for treating cancer patients with EGFR kinase inhibitors that incorporate the above methodology are also provided. Additionally, methods are provided for the identification of new biomarkers that are predictive of responsiveness of tumors to EGFR kinase inhibitors. Furthermore, methods for the identification of agents that restore the sensitivity of tumor cells that have undergone EMT to inhibition by EGFR kinase inhibitors are also provided.

公开(公告)号：US20060204505A1

公开(公告)日：2006-09-14

申请号：US11370304

申请日：2006-03-07

申请人： Mark Sliwkowski ,  David Eberhard

发明人： Mark Sliwkowski ,  David Eberhard

IPC分类号： A61K39/395 ,  G01N33/574 ,  A61K31/7072

CPC分类号： C07K16/32 ,  A61K2039/505 ,  C12Q1/485 ,  G01N33/5011 ,  G01N33/574 ,  G01N33/57407 ,  G01N33/57415 ,  G01N33/57449 ,  G01N2800/52

摘要： Tumors are identified as responsive to treatment with HER dimerization inhibitors (HDIs) are identified by treating a HER expressing tumor with an HDI (which may be the same or different from that contemplated for treatment), and determining the reactivity of the tumor with the HDI. Lack of or diminished reactivity is an indication that the tumor is likely to be responsive to treatment with the dimerization ihibitor.

摘要翻译： 通过用HDI处理HER表达的肿瘤（其可以与预期的治疗相同或不同）来鉴定肿瘤对HER治疗的响应，二聚抑制剂（HDIs）是通过治疗HER表达的肿瘤来确定的，并且确定肿瘤与HDI的反应性 。 缺乏或减少的反应性表明肿瘤可能对二聚化抑制剂的治疗有反应。